Clinical Trials
3
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (66.7%)Phase 1
1 (33.3%)A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Eleos, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT02243124
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to Frontline Induction Course
Phase 2
Withdrawn
- Conditions
- Acute Myelogenous Leukemia
- Interventions
- First Posted Date
- 2009-08-28
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Eleos, Inc.
- Registration Number
- NCT00967512
Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML
Phase 2
Completed
- Conditions
- Acute Myelogenous Leukemia
- Interventions
- First Posted Date
- 2003-12-23
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Eleos, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT00074737
- Locations
- 🇺🇸
University of California, San Diego, La Jolla, California, United States
🇺🇸University of Miami Health Center, Miami, Florida, United States
🇺🇸Washington University Medical Center (Siteman Cancer Center), St. Louis, Missouri, United States
News
No news found